Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07169799

Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE)

The purpose of this study is to evaluate the impact of cryotherapy spray treatment for eradication of gastric antral vascular ectasia by measuring the change in hemoglobin levels and transfusion requirements in the first 6 months of cryotherapy treatment compared to the previous 6 months

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Mayo Clinic in Florida

Jacksonville, Florida, 32224, United States

Location status: Recruiting

Location contact

Stephanie McNew, B.S.

CONTACT

[email protected]

904-953-0580

Swathi Eluri, M.D.

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of antral-predominant GAVE: Endoscopic confirmation of gastric-antral vascular ectasia affecting the antrum, without severe portal-hypertensive gastropathy. Sub-classify as nodular or non-nodular GAVE.
  • Age: ≥ 18 years at the time of consent.
  • Recent transfusion-dependent anemia
  • ≥ 1 packed-RBC transfusion for GAVE-related bleeding within the last 6 months to maintain hemoglobin (Hgb) > 8 g/dL (or > 7 g/dL if no coronary/vascular disease).
  • Standard-of-care transfusion thresholds:
  • If no coronary artery/vascular disease (CVD): transfuse 2 units when Hgb < 7 g/dL.
  • If CVD present: transfuse 2 units when Hgb < 8 g/dL.
  • After any transfusion, re-check Hgb within 1 week and repeat transfusion per the same criteria as needed.
  • Documented transfusion history:

o Medical records must show indication that each transfusion was for presumed GAVE-related bleeding.

  • Treatment status:

o Either treatment-naïve or ≤ 3 prior endoscopic ablation sessions for GAVE.

  • Baseline data availability: Participant records must include endoscopic treatment dates, hemoglobin values, and transfusion data for 6 months prior to enrollment (extension up to 9 months permitted if data unavailable). Required elements:
  • total number of transfusions,
  • total number of prior endoscopic treatments, and calculated change in hemoglobin from baseline: Δ Hgb = Hgb(T-6 mo) - Hgb(T0) [extendable to Hgb(T-9 mo) if 6-month data are incomplete]
  • Capacity to consent: Able and willing to provide written informed consent.

Exclusion criteria

  • Other gastrointestinal pathology

o Active peptic-ulcer disease, inflammatory bowel disease, severe portal-hypertensive gastropathy, or untreated esophageal/gastric varices.

  • Coagulopathy

o Known bleeding disorder or acquired coagulopathy not attributable to GAVE.

  • Severe comorbidity / high procedural risk
  • Advanced heart failure, severe renal impairment, or any condition classified ASA IV or V.
  • Estimated life-expectancy < 6 months.
  • Karnofsky performance status ≤ 40.
  • Deemed unfit for endoscopic procedures by the treating physician.
  • Pregnancy / lactation:

o Pregnant or breastfeeding, or planning pregnancy within 6 months of consent.

  • Prior incompatible therapy

o Previous cryoballoon ablation for GAVE.

  • Ability to participate
  • Unable or unwilling to comply with the protocol or follow-up schedule.
  • Unable or unwilling to provide written informed consent.

Treatment and study plan

trūFreeze® Spray Cryotherapy System (STERIS Endoscopy)

Other

This treatment consists of performing a diagnostic EGD to identify GAVE lesions. A catheter advances through the therapeutic channel to treat target areas with cryotherapy.

Other names: Procedure: EGD and truFreeze® spray-cryotherapy

Primary outcomes

  1. Evaluate the clinical benefit of truFreeze® spray-cryotherapy in patients with gastric-antral vascular ectasia.

    Time frame: over 6 month period

    Changes in mean hemoglobin concentrations.

    Total number of packed-RCB units during a 6-month period after treatment and 6-months prior to treatment (retrospective review)

Secondary outcomes

  1. Endoscopic success.

    Time frame: over 6 month period

    Endoscopic success (as assessed by independent endoscopic image review) measured safety of the cryotherapy procedure (adverse event tracking and assessments) change in means of patient's quality of life (measured by SF-12)

Study contacts

Contact information is provided by the study sponsor or research team.

Kristen Lozano

CONTACT

[email protected]

Stephanie McNew

CONTACT

[email protected]

904-953-0580

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Official study title

Evaluating the Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE)

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Sep 12, 2025
Registry last updated
Apr 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.